Kasahara K, Kono T, Sato Y, Okubo K, et al. Risk-benefit stratification for immune checkpoint inhibitor therapy in head and neck cancer based on immune-related adverse events and treatment discontinuation using routine clinical indicators beyond PD-L1 expression. Oral Oncol 2026;176:107938.
PMID: 41861715